Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELUCIDATE: Dapagliflozin for LV Function in T2D
NCT03871621Phase 4Completed
- Sponsor
- Mackay Memorial Hospital
- Start
- Apr 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Mackay Memorial Hospital. Primary endpoints: Cardiac Global Longitudinal Strain at 24 weeks and Left Ventricular Mass Index at 24 weeks. Started Apr 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03871621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871621.